Beta 2-agonists use during pregnancy and the risk of congenital malformations

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 91, Issue 11, 2011, Pages 937-947

  Eltonsy, Sherif ^a,b   Forget, Amélie ^a,b   Blais, Lucie ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Administrative databases; Asthma; Cohort studies; Congenital malformations; First trimester

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIASTHMATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CANADA; CHILD; CONGENITAL MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; CONGENITAL DISORDER; NEWBORN; PREGNANCY COMPLICATION; RISK FACTOR; TIME;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CONGENITAL ABNORMALITIES; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 80855147843     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.22850     Document Type: Article

References (61)

1. Alexander S, Dodds L, Armson BA. 1998. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol 92: 435-440.
2. Bakhireva LN, Jones KL, Schatz M, et al. 2005. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 116: 503-509.
3. Bateman ED, Boushey HA, Bousquet J, et al. 2004. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170: 836-844.
4. Blais L, Beauchesne MF, L'vesque S. 2006. Socioeconomic status and medication prescription patterns in pediatric asthma in Canada. J Adolesc Health 38: 607.e9-607.e16.
5. Blais L, Beauchesne MF, Lemière C, Elftouh N. 2009. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 124: 1229-1234.
6. Blais L, Forget A. 2008. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J Allergy Clin Immunol 121: 1379-1384.
7. Blais L, Kettani FZ, Elftouh N, Forget A. 2010. Effect of maternal asthma on the risk of specific congenital malformations: a population-based cohort study. Birth Defects Res A Clin Mol Teratol 88: 216-222.
8. Blais L, Lemiere C, Berbiche D, et al. 2004. Validation of asthma diagnostic codes in the administrative health databases of Quebec, Canada. Pharmacoepidemiology and Drug Safety 13: S32.
9. Boulet LP, Becker A, Bérubé D, et al. 1999. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 161( 11 Suppl): S1-61.
10. Brent RL. 2001. Addressing environmentally caused human birth defects. Pediatr Rev 22: 153-165.
11. Brent RL, Beckman DA. 1990. Environmental teratogens. Bull N Y Acad Med 66: 123-163.
12. Carmichael SL, Shaw GM. 1999. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 86: 242-244.
13. Chap TL. 2003. Introductory biostatistics. Wiley-Interscience.
14. Clark JM, Hulme E, Devendrakumar V, et al. 2007. Effect of maternal asthma on birthweight and neonatal outcome in a British inner-city population. Paediatr Perinat Epidemiol 21: 154-162.
15. Demissie K, Breckenridge MB, Rhoads GG. 1998. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 158: 1091-1095.
16. Dombrowski M. 2006. Outcomes of pregnancy in asthmatic women. Immunol Allergy Clin North Am 26: 81-92.
17. Dombrowski MP, Schatz M, Wise R, et al. 2004. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol 190: 737-744.
18. Eickelberg O, Roth M, Lörx R, et al. 1999. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274: 1005-1010.
19. Firoozi F, Lemière C, Beauchesne MF, et al. 2007. Development and validation of database indexes of asthma severity and control. Thorax 62: 581-587.
20. Gluck JC, Gluck PA. 2005. Asthma controller therapy during pregnancy. Am J Obstet Gynecol 192: 369-380.
21. Greenland S. 1989. Modeling and variable selection in epidemiologic analysis. Am J Public Health 79: 340-349.
22. Health Statistics USNCF, National Vital Statistics R. 2007. Births: Final data for 2005.
23. Heinonen OP, Slone D, Shapiro S. 1977. Birth defects and drugs in pregnancy. Littleton: Publishing Sciences Group, Inc.
24. John Y. 2007. Epidemiology and prevention: a systems-based approach. Oxford University Press.
25. Jones KL, Johnson DL, Van Maarseveen ND, et al. 2002. Salmeterol use and pregnancy outcome: a prospective multi-center study. J Allergy Clin Immunol 109: S156.
26. Källén B, Otterblad Olausson P. 2007. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol 63: 383-388.
27. Källén BA, Otterblad Olausson PO. 2003. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17: 255-261.
28. Kips JC, Pauwels RA. 2001. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 164: 923-932.
29. Kleinbaum DG, Lawrence LK, Keith EM, Azhar N. 2008. Applied regression analysis and multivariable methods. Duxbury Press.
30. Kung HC, Hoyert DL, Xu JQ, Murphy SL. 2010. E-stat deaths: preliminary data for 2005 health E-stats. Hyattsville, MD: US Department of Health and Human Services, CDC;2007.
31. Lao TT, Huengsburg M. 1990. Labour and delivery in mothers with asthma. Eur J Obstet Gynecol Reprod Biol 35: 183-190.
32. Lin S, Herdt-Losavio M, Gensburg L, et al. 2009. Maternal asthma, asthma medication use, and the risk of congenital heart defects. Birth Defects Res A Clin Mol Teratol 85: 161-168.
33. Lin S, Munsie JP, Herdt-Losavio ML, et al. 2008. Maternal asthma medication use and the risk of gastroschisis. Am J Epidemiol 168: 73-79.
34. Luskin AT. 1999. An overview of the recommendations of the Working Group on Asthma and Pregnancy. National Asthma Education and Prevention Program. J Allergy Clin Immunol 103(2 Pt 2): S350-S353.
35. Mann RD, Kubota K, Pearce G, Wilton L. 1996. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15, 407 patients. J Clin Epidemiol 49: 247-250.
36. Martel MJ, Rey E, Beauchesne MF, et al. 2007. Use of short-acting beta2-agonists during pregnancy and the risk of pregnancy-induced hypertension. J Allergy Clin Immunol 119: 576-582.
37. Martel MJ, Rey E, Beauchesne MF, et al. 2005. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 330: 230.
38. Murphy VE, Gibson PG, Smith R, Clifton VL. 2005. Asthma during pregnancy: mechanisms and treatment implications. Eur Respir J 25: 731-750.
39. National Heart, Lung, and Blood Institute;National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. 2005. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 115: 34-46.
40. Olesen C, Thrane N, Nielsen GL, et al. 2001. A population-based prescription study of asthma drugs during pregnancy: changing the intensity of asthma therapy and perinatal outcomes. Respiration 68: 256-261.
41. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. 2000. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385-392.
42. Polifka JE, Friedman JM. 1999. Clinical teratology: identifying teratogenic risks in humans. Clin Genet 56: 409-420.
43. Quebec. 1997. Statistiques annuelles. Quebec: Regie de l'assurance maladie.
44. Rodriguez-Pinilla E, Martinez-Frias ML. 1998. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 58: 2-5.
45. Rothman KJ, Greenland S, Lash TL. 2008. Modern epidemiology. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p 758.
46. Schatz M, Dombrowski MP, Wise R, et al. 2004. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 113: 1040-1045.
47. Schatz M, Zeiger RS, Harden KM, et al. 1988. The safety of inhaled beta-agonist bronchodilators during pregnancy. J Allergy Clin Immunol 82: 686-695.
48. Schatz M, Zeiger RS, Harden K, et al. 1997. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 100: 301-306.
49. Schatz M, Zeiger RS, Hoffman CP. 1990. Intrauterine growth is related to gestational pulmonary function in pregnant asthmatic women. Kaiser-Permanente Asthma and Pregnancy Study Group. Chest 98: 389-392.
50. Statistics Canada. 2010. Ten leading causes of infant death, by sex, Canada, 2000 to 2004.
51. Tamási L, Somoskövi A, Müller V, et al. 2006. A population-based case-control study on the effect of bronchial asthma during pregnancy for congenital abnormalities of the offspring. J Asthma 43: 81-86.
52. Tamblyn R, Lavoie G, Petrella L, Monette J. 1995. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Qu'bec. J Clin Epidemiol 48: 999-1009.
53. Tan KS, Thomson NC. 2000. Asthma in pregnancy. Am J Med 109: 727-733.
54. Tata LJ, Lewis SA, McKeever TM, et al. 2008. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. Thorax 63: 981-987.
55. Thong M, Lim C, Fatimah H. 1998. Undescended testes: incidence in 1, 002 consecutive male infants and outcome at 1 year of age. Pediatr Surg Int 13: 37-41.
56. Vilain A, Otis S, Forget A, Blais L. 2008. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf 17: 345-353.
57. Vittinghoff E, Shiboski S, Glidden D, McCulloch C. 2005. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. New York: Springer. xv, p 340.
58. Wilton LV, Pearce GL, Martin RM, et al. 1998. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 105: 882-889.
59. Wilton LV, Shakir SA. 2002. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. Drug Saf 25: 213-223.
60. Yagel S, Silverman NH, Gembruch U. 2009. Fetal cardiology: embryology, genetics, physiology, echocardiographic evaluation, diagnosis, and perinatal management of cardiac diseases. 2nd ed. New York: Informa Healthcare. xv, p 780.
61. Zeger SL, Liang KY, Albert PS. 1988. Models for longitudinal data: a generalized estimating equation approach. Biometrics 44: 1049-1060.